Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Corcept Therapeutics (CORT) stock in plain English

Free brief · no signupStart here
CORTPublished Nov 15, 2026
Corcept Therapeutics Inc
Healthcare · Biotechnology
Sells a daily oral medication to control high blood sugar in adults with Cushing syndrome. Discovers and tests other cortisol-modulating drugs for metabolic diseases and cancer.
Assets:
Korlym commercial productApproved oral treatment generating nearly all commercial revenue
Relacorilant late-stage assetSelective cortisol modulator completing phase three clinical trials
Menlo Park headquartersCentral corporate office and research base in California
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

84
OPS ScoreOperating finances
Latest quote
-4.15%$64.98
$7.11B
51.3×
$963.63M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was CORT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Corcept Therapeutics (CORT) do?

Corcept Therapeutics Inc (CORT) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells a daily oral medication to control high blood sugar in adults with Cushing syndrome. Discovers and tests other cortisol-modulating drugs for metabolic diseases and cancer. It discovers and sells medications that treat metabolic and oncologic disorders by regulating cortisol activity. It is worth $7.11B on the market and sold $963.63M over the last year.

Market cap
$7.11B
P/E ratio
51.3×
Annual sales
$963.63M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 15, 2026

Brands and businesses behind CORT

  • Korlym: It treats high blood sugar in adults with endogenous Cushing syndrome through specialty pharmacy prescription sales.

CORT’s flags, in plain English

Each flag is a number from Corcept Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Low debt

Low debt, only 1% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 98.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Stupid Cash

Can pay this year's bills 3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Profit with Caveats

Bottom-line profit of $162M in the 12 months to Sep 30, 2026, next to $111M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about CORT

How big is Corcept Therapeutics?

Corcept Therapeutics’ market cap is $7.11B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $963.63M: what customers paid the company over the last year, before any costs.

What is CORT’s P/E ratio?

CORT’s P/E ratio is 51.3×. Investors pay about 51.3 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with CORT?

The business relies on a single approved drug for nearly all its current sales. That is one risk on Corcept Therapeutics’ card. Its first risk flag is Profit with Caveats, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Corcept Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CORT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card